Bafna Pharmaceuticals Ltd.
Snapshot View

View in App

Prices View details

130.25 +3.25 ▲2.6%

18 May 2022, 04:01:00 PM
Volume: 105

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bafnapharma.com
Market Cap 308.12 Cr.
Enterprise Value(EV) 310.45 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 3.72 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 35.00 Trailing Twelve Months Ending 2021-12
Industry PE 28.96 Trailing Twelve Months Ending 2021-12
Book Value / Share 28.18 Trailing Twelve Months Ending 2021-12
Price to Book Value 4.62 Calculated using Price: 130.25
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 2.37 Cr. 23,656,335 Shares
FaceValue 10
Company Profile

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.

The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.

It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.

The company’s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.

Product Range:

  • Antibacterials
  • Antipyretics
  • Antconvulsants
  • Anxiolytics
  • Pain management
  • Anthelmintics
  • Antifungal
  • Appetite stimulants
  • Antidiarrhoeals
  • Antiemetics
  • Hypnotics
  • Antacids and antiulcerants
  • Vitamin and dietery preparation
  • Cough and cold preparations
  • Antiasthmatics
  • Calcium preparations
  • Antihypertensives
  • Antidiabetics

Achievements/ Awards:

  • BAFNA was awarded the WHO GMP in the year 1995.
  • Bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
  • Accorded the status of an ‘Export House’ in recognition of its excellent export performance.
  • Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
  • 2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
  • MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
  • 2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
  • Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
  • 2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
  • Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.56%
1 Week
+2.56%
1 Month
+0.97%
3 Month
-14.39%
6 Month
+0.08%
1 Year
-4.96%
2 Year
+1234.53%
5 Year
+360.25%
10 Year
+192.70%

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 6.89 2.25 9.22 -18.69 -37.05 -40.37 -64.36 -22.93 22.26
Return on Capital Employed (%) 11.19 9.15 12.56 -0.04 -5.98 -6.97 -20.90 -2.95 10.42
Return on Assets (%) 1.72 0.57 2.99 -6.58 -10.49 -11.17 -15.90 -1.96 7.40

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 67 69 72 59 45 41 21 51 57 65
Non Curr. Liab. 29 27 14 39 42 28 29 3 5 7
Curr. Liab. 147 126 100 87 81 59 71 17 24 21
Minority Int.
Equity & Liab. 243 223 185 185 167 128 121 71 86 93
Non Curr. Assets 69 66 68 65 90 79 72 35 37 39
Curr. Assets 167 149 117 119 77 48 48 36 50 54
Misc. Exp. not W/O 6 8 1
Total Assets 243 223 185 185 167 128 121 71 86 93

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 167 178 143 85 65 47 44 42 71 92
Other Income 3 1 1 1 1 31 0 0 1 1
Total Income 170 179 144 87 66 78 44 43 72 93
Total Expenditure -146 -156 -117 -83 -70 -82 -57 -41 -61 -76
PBIDT 24 23 26 4 -4 -4 -13 1 11 17
Interest -11 -12 -12 -12 -11 -7 -2 0 -1 -1
Depreciation -8 -8 -5 -4 -4 -4 -3 -3 -4 -6
Taxation -1 -1 0 0 1 -2 -2
Exceptional Items -3 -2
PAT 4 1 6 -12 -18 -16 -20 -2 6 9
Adjusted EPS 2 1 3 -7 -10 -7 -8 -8 2 4

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 28 35 1 9 -3 20 -7 -1 -34 -14
Cash Fr. Inv. -37 -6 -5 56 -1 -14 38 4 33 -5
Cash Fr. Finan. -1 -11 -14 -66 4 -5 -31 -2 7 12
Net Change -9 18 -18 0 0 0 0 6 -7
Cash & Cash Eqvt 2 21 2 2 3 3 3 3 8 2

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 26.40 26.40 92.64 92.64 91.74 90.39 90.40 90.42 90.42
Public 73.60 73.60 7.36 7.36 8.26 9.61 9.60 9.58 9.58
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 50.96 50.96 1.45 1.45 1.47 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 09 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company BAFNA PHARMACEUTICALS LTD.
2 CIN NO. L24294TN1995PLC030698
3 Report filed for FY 2021-2022
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* 2021-2022 2022-23
5 Incremental borrowing done in FY (T)(a) 1.27
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)2021-2022 2022-2023
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-Roopa Ravikumar
Designation :-Company Secretary
Name of the Chief Financial Officer :- M SRIDHAR
Designation : -CHIEF FINANCIAL OFFICER

Date: 09/05/2022
Wed, 13 Apr 2022
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
We are enclosing herewith Certificate dated 4th April 2022 issued by Cameo Corporate Services Limited Registrar and Transfer Agent (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018.
Mon, 11 Apr 2022
Certificate From Practicing Company Secretary For The Half Year Ended 31St March 2022
Certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (LODR) Regulations 2015 for the half year ended 31st March 2022 is hereby enclosed for your reference.

Technical Scans View Details

Wed, 18 May 2022
High Delivery Percentage High Delivery Percentage
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 215,700.21 899.00 +0.8%
Divi's Laboratories Ltd. 115,623.51 4,355.45 +1.2%
Cipla Ltd. 76,889.38 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. 65,126.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. 53,689.19 3,734.00 -2.1%
Gland Pharma Ltd. 51,396.43 3,122.95 +0.6%
Piramal Enterprises Ltd. 47,255.41 1,980.00 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.47 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 45.03 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 30.55 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 24.64 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 47.37 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 43.33 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 38.03 1,980.00 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.17 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.67 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 3.69 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 3.39 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.70 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 7.48 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.33 1,980.00 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 0.10 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,980.00 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,980.00 -0.2%